Managers / Q4 2019 · view latest →
Foresite Capital Management IV, LLC
CIK 0001704132 · 9200 W. SUNSET BOULEVARD, SUITE 515, WEST HOLLYWOOD, CA, 90069 · 415-877-4887
Summary
Foresite Capital Management IV, LLC reported $232M in U.S.-listed holdings across 14 positions for Q4 2019.
Its largest position, Aerie Pharmaceuticals, represents 15.7% of the portfolio.
Compared with Q3 2019, the fund opened 2 new positions and exited 5.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 96.5% · $224M
- Other · 3.5% · $8M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ABUSArbutus BioPharma Corp. | NEW | +3.71M | 3.71M | +$10M | $10M |
| KURAKura Oncology, Inc. | NEW | +68.0K | 68.0K | +$935,000 | $935,000 |
| Turning Point Therapeutics, Inc. | SOLD OUT | −1.83M | 0 | −$69M | $0 |
| Biohaven Pharmaceutical Holding Company Ltd. | SOLD OUT | −425.8K | 0 | −$18M | $0 |
| Orchard Therapeutics PLC | SOLD OUT | −557.7K | 0 | −$7M | $0 |
| RYTMRhythm Pharmaceuticals, Inc. | SOLD OUT | −234.5K | 0 | −$5M | $0 |
| IMMUImmunomedics, Inc. | SOLD OUT | −367.6K | 0 | −$5M | $0 |
| ASNDAscendis Pharma A/S | TRIMMED | −176.4K | 69.0K | −$14M | $10M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | Aerie Pharmaceuticals, Inc. | COM | 15.66% | $36M | 1.50M |
| 2 | The Medicines Company | COM | 14.78% | $34M | 403.2K |
| 3 | INSMInsmed Incorporatedhistory → | COM | 14.73% | $34M | 1.43M |
| 4 | CYTKCytokinetics Incorporatedhistory → | COM NEW | 10.98% | $25M | 2.40M |
| 5 | FULCFulcrum Therapeutics, Inc.history → | COM | 10.77% | $25M | 1.50M |
| 6 | Myokardia, Inc. | COM | 8.19% | $19M | 260.4K |
| 7 | VYGRVoyager Therapeutics, Inc.history → | COM | 5.00% | $12M | 830.6K |
| 8 | ABUSArbutus BioPharma Corp.history → | COM | 4.44% | $10M | 3.71M |
| 9 | ASNDAscendis Pharma A/Shistory → | SPONSORED ADR | 4.14% | $10M | 69.0K |
| 10 | OptiNose, Inc. | COM | 3.46% | $8M | 870.8K |
| 11 | SIBNSI-BONE, Inc.history → | COM | 2.86% | $7M | 308.2K |
| 12 | ALECAlector, Inc.history → | COM | 2.63% | $6M | 353.5K |
| 13 | CymaBay Therapeutics, Inc. | COM | 1.96% | $5M | 2.32M |
| 14 | KURAKura Oncology, Inc. | COM | 0.40% | $935,000 | 68.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $237M | 8 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $230M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $183M | 6 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $124M | 6 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $111M | 5 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $109M | 4 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $153M | 5 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $149M | 4 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $198M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $198M | 5 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $180M | 7 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $203M | 7 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $193M | 8 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $234M | 8 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $311M | 8 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $371M | 8 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $357M | 9 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $486M | 9 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $679M | 12 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $740M | 13 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $835M | 13 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $921M | 13 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $443M | 15 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $205M | 12 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $81M | 11 | May 28, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2019 | $232M | 14 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $309M | 19 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $354M | 22 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $278M | 16 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $218M | 18 | Feb 13, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.